
==== Front
Acta Neuropathol
Acta Neuropathol
Acta Neuropathologica
0001-6322
1432-0533
Springer Berlin Heidelberg Berlin/Heidelberg

2796
10.1007/s00401-024-02796-w
Original Paper
Disability independent of cerebral white matter demyelination in progressive multiple sclerosis
Singh Vikas 1
Zheng Yufan 2
Ontaneda Daniel 3
Mahajan Kedar R 13
Holloman Jameson 13
Fox Robert J 3
Nakamura Kunio 2
http://orcid.org/0000-0001-6682-3737
Trapp Bruce D trappb@ccf.org

1
1 https://ror.org/03xjacd83 grid.239578.2 0000 0001 0675 4725 Department of Neurosciences, NC30, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 USA
2 https://ror.org/03xjacd83 grid.239578.2 0000 0001 0675 4725 Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA
3 https://ror.org/03xjacd83 grid.239578.2 0000 0001 0675 4725 Mellen Center for Treatment and Research in MS, Cleveland Clinic, Cleveland, OH USA
31 8 2024
31 8 2024
2024
148 1 3412 7 2024
20 8 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The pathogenic mechanisms contributing to neurological disability in progressive multiple sclerosis (PMS) are poorly understood. Cortical neuronal loss independent of cerebral white matter (WM) demyelination in myelocortical MS (MCMS) and identification of MS patients with widespread cortical atrophy and disability progression independent of relapse activity (PIRA) support pathogenic mechanisms other than cerebral WM demyelination. The three-dimensional distribution and underlying pathology of myelinated T2 lesions were investigated in postmortem MCMS brains. Postmortem brain slices from previously characterized MCMS (10 cases) and typical MS (TMS) cases (12 cases) were co-registered with in situ postmortem T2 hyperintensities and T1 hypointensities. T1 intensity thresholds were used to establish a classifier that differentiates MCMS from TMS. The classifier was validated in 36 uncharacterized postmortem brains and applied to baseline MRIs from 255 living PMS participants enrolled in SPRINT-MS. Myelinated T2 hyperintensities in postmortem MCMS brains have a contiguous periventricular distribution that expands at the occipital poles of the lateral ventricles where a surface-in gradient of myelinated axonal degeneration was observed. The MRI classifier distinguished pathologically confirmed postmortem MCMS and TMS cases with an accuracy of 94%. For SPRINT-MS patients, the MRI classifier identified 78% as TMS, 10% as MCMS, and 12% with a paucity of cerebral T1 and T2 intensities. In SPRINT-MS, expanded disability status scale and brain atrophy measures were similar in MCMS and TMS cohorts. A paucity of cerebral WM demyelination in 22% of living PMS patients raises questions regarding a primary role for cerebral WM demyelination in disability progression in all MS patients and has implications for clinical management of MS patients and clinical trial outcomes in PMS. Periventricular myelinated fiber degeneration provides additional support for surface-in gradients of neurodegeneration in MS.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00401-024-02796-w.

Keywords

Multiple sclerosis
Neuropathology
Neurodegeneration
MRI
Demyelination
US NATIONAL INSTITUTE OF HEALTHR35NS09730 Trapp Bruce D http://dx.doi.org/10.13039/100000890 National Multiple Sclerosis Society RFA-2203-39319 Trapp Bruce D US DEPARTMENT OF DEFENCEW81XWH2110787 Nakamura Kunio issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects approximately 1 million individuals in the United States and 2.8 million individuals worldwide [36]. Most people with MS (PwMS) have a clinical course initially characterized by relapses and remissions that eventually evolves into a progressive course where relapses are rare and disability progression is continuous and irreversible [20, 33, 42, 46]. Immune-modulating therapies reduce gadolinium-enhanced cerebral white matter (WM) lesions and clinical relapses but have less robust effects on disability progression where the cause is neurodegeneration and therapeutic targets include neuroprotection, remyelination, and modulation of innate immunity [29]. Magnetic resonance imaging (MRI) of cerebral WM plays a critical role in the diagnosis and therapeutic management of individuals with relapsing-remitting MS (RRMS) and serves as an outcome measure in clinical trials designed to reduce cerebral WM demyelinating lesions [36]. MRI metrics for disease progression in progressive MS are more challenging and include abnormalities in cerebral WM and brain volume measures. While T2 lesion volume usually increases with disability progression, it accounts for less than 30% of the variance in the rate of brain atrophy, [15, 23, 38] and 45% of T2-weighted lesions in secondary progressive postmortem MS brains are myelinated [9, 16]. It remains to be determined if myelinated cerebral WM T2 hyperintensities are associated with a novel pathological process that is independent of cerebral WM demyelination.

A subset of postmortem MS brains in the Cleveland Clinic MS autopsy database (12/100) has a paucity of cerebral WM demyelination and are referred to as myelocortical MS (MCMS) based upon spinal cord and subpial cortical demyelination [43]. Despite the lack of cerebral WM demyelination, neuronal loss in 5 cortical areas was similar to that detected in postmortem MS brains with cerebral WM demyelination [43]. Global cortical atrophy in MS patients that have disability progression independent of relapse activity (PIRA) [3, 22, 34, 44, 45] and MS patients with acute clinical events with stable MRIs (ACES) [18] also raise questions regarding the role of cerebral WM demyelination as the major cause of disability in MS. While cerebral WM demyelination contributes to irreversible disability progression, it is unlikely to be the sole driving factor in progressive MS patients [4, 41]. A challenge for the MS research community is to identify causes of the permanent neurological disability that occur independent of cerebral WM demyelination. Development of MRI sequences that reliably identify myelinated cerebral WM in living MS patients would be beneficial in this regard.

The three-dimensional distribution of myelinated T2 hyperintensities in MCMS remains unknown. As T1-hypointense lesions are more sensitive for demyelination compared to T2 lesions, a multiparametric approach using T1 hypointensity thresholds may reliably distinguish myelinated from demyelinated WM lesions and possibly identify living MCMS patients [26]. There is obvious value in identifying living MCMS patients because their inclusion in a remyelinating clinical trial that focuses on cerebral T2 lesions could obscure potential benefits since T2 lesions in MCMS are not demyelinated. Identification of myelinated axonal pathology in MCMS may also identify novel treatment opportunities for progressive MS.

The present study investigates MRI and pathological changes in MCMS. We determined the three-dimensional distribution of myelinated T2 hyperintensities in MCMS and investigated the pathological correlates of myelinated T2 hyperintensities. We developed an MRI-based classifier that identified postmortem MCMS cases and applied it to baseline MRIs of 255 progressive MS patients enrolled in the Phase II, placebo-controlled, randomized, double-blind, multi-center clinical trial of ibudilast in progressive MS (SPRINT-MS, NCT01982942) [17].

Materials and methods

Brain tissues

Postmortem brains and spinal cords were obtained from patients with MS through the Cleveland Clinic rapid autopsy protocol [10]. Consent for in situ postmortem MRI and procurement of brains was obtained prior to death from living patients or family members after death. This study was approved by the Institutional Review Board of the Cleveland Clinic, Cleveland, OH, USA. Twelve previously characterized MCMS and 12 typical MS (TMS) brains were utilized for pathological studies [43]. MRI data from 2 MCMS brains are not available. Age-matched postmortem brains from 8 individuals without clinical indications or pathological evidence of neurological disease were used as controls for pathological studies. Clinical characteristics of these 30 brain donors have been described previously [43].

Postmortem in situ brain MRI

Postmortem in situ MRIs were acquired prior to brain removal using standardized MRI acquisition protocols (Table 1) [16, 43]. MRI acquisition protocols for PwMS are described in Table 1. A schematic overview of the experimental workflow is provided in Fig. S1.Table 1 Parameters of MRI sequences

MRI sequence	Repetition time (ms)	Inversion time (ms)	Echo time (ms)	FOV (mm)	Slice thickness (mm)	Matrix size	Scanner	
Postmortem 3D FLAIR	6500	2000	403	230	5	256 × 256	Siemens 1.5T, 3T	
Postmortem 3D T1w (MPRAGE)	1860	NA	2.8	240	0.94	256 × 256	
Postmortem 3D T1w (FLASH)	18	NA	5	192	1	256 × 192	
SPRINTMS 3D FLAIR	[9000, 13580]	2500	[77.0, 99.2]	[192, 256]	3	256 × 256	Siemens or GE 3T	
SPRINTMS 3D T1w (FLASH)	[20, 28]	NA	6	[192, 256]	1	256 × 256	

Postmortem MRI classifier

An MRI classifier was developed that differentiated MCMS and TMS based upon T2 and T1 lesion volumes using MRIs of previously-characterized postmortem cases (10 MCMS and 12 TMS brains) [43]. T2 lesions were first segmented automatically using a previously published in-house segmentation method and manually corrected when necessary [14]. For T1 lesion segmentation, mean and standard deviation (SD) intensity of cortical grey matter (GM) was calculated for each brain using the formula: Threshold value = Mean T1 intensity of GM–k (optimal scaling factor) × SD of GM T1 intensity. Various thresholds of these cortical GM T1 intensities were applied to the classifier (Table 2). The T1 intensity threshold that most reliably distinguished MCMS and TMS was 1.7 × SD below the mean cortical GM intensity. The value of k = 1.7 was identified from a receiver-operating characteristics (ROC) analysis of T1 volume and proportion of T2 lesions occupied by T1 lesions (T1/T2 %) on the same postmortem cases using an in-house deep learning method (Table 2; Fig. 1a and b). The 3D renderings of T2 hyperintensities and T1 hypointensities were created using MRIcroG [37].Table 2 Testing k values to optimize T1 volumes and T1/T2% to identify MCMS

k (Scaling factor)	T1 volume	T1/T2 %	
specificity	sensitivity	accuracy	cut-off	specificity	sensitivity	accuracy	cut-off	
1	0.75	0.8	0.77	1.976	0.75	0.8	0.78	8.8	
1.1	0.75	0.8	0.77	1.788	0.75	0.8	0.78	7.4	
1.2	0.75	0.8	0.77	1.581	0.83	0.8	0.82	5.2	
1.3	0.75	0.8	0.77	1.391	0.75	0.8	0.73	5.3	
1.4	0.75	0.8	0.77	1.213	0.75	0.8	0.73	4.4	
1.5	0.75	0.7	0.73	0.864	0.67	1	0.82	7.3	
1.6	0.75	0.7	0.73	0.796	0.67	1	0.82	6.4	
1.7	0.75	0.9	0.82	0.747	0.92	0.7	0.82	1.9	
1.8	0.75	0.8	0.78	0.601	0.92	0.7	0.82	1.6	
1.9	0.83	0.8	0.82	0.49	0.92	0.7	0.82	1.3	
2	0.75	0.8	0.78	0.448	0.67	1	0.82	2.8	

Fig. 1 Development of an MRI-based classifier to identify the MCMS subgroup. a-b Receiver operating characteristic (ROC) curves for T1 volume (a) and T1/T2% ratio (b) for discriminating MCMS from TMS. c-d The optimal threshold for T1 hypointensities derived from ROC curves is depicted as probability maps of T1 lesions in TMS (c) and MCMS (d)

T1 lesion probability map

Each MRI was nonlinearly registered to the International Consortium for Brain Mapping (ICBM) standard template using ANTS. The nonlinear warp was used to transform T2 lesions maps and the thresholded T1 lesion maps into the standard space where the probability maps were created. The T1 lesion probability map was blurred by Gaussian filter to account for potential spatial mismatch.

Validation of the MRI classifier

The MRI classifier was validated on 36 uncharacterized postmortem brains with T2 lesion volumes > 2 ml (required to distinguish MCMC and TMS) and age at time of death < 65 years (upper age limit for progressive MS clinical trials) [5–7, 17]. Brain slices (24–28 cm thick) from all 36 brains were examined macroscopically for cerebral WM hyperpigmentation, measured, and expressed as cm2. For MCMS brains identified by the MRI classifier, MRI images were co-registered with cm-thick brain slices that contained the occipital horn of the lateral ventricle to confirm expansive T2 hyperintensities. These cm-thick brain slices were then embedded in paraffin, sectioned, and stained for myelin with proteolipid protein (PLP) antibodies. MCMS cases were identified by a paucity of macroscopic lesions in cm-thick hemispheric brain slices (total cerebral WM hyperpigmentations per hemisphere < 0.4 cm2)[43], the absence of demyelinated lesions in the PLP-stained hemispheric sections, the presence of demyelinated subpial cortical lesions in PLP-stained hemispheric sections, and the presence of demyelinated lesions in PLP-stained 30 µm-thick sections from spinal cord.

Co-registration of MRI and tissue slices

Following the postmortem in situ MRI, the cadaver was transported to the morgue for brain and tissue collection. One cerebral hemisphere was separated and fixed in 4% paraformaldehyde for at least 9 weeks [10]. The long-fixed brain hemisphere was scanned using a high-resolution T1-weighted image in a custom-made slicing box with MRI-visible markers. After scanning, the brain tissue was sliced into 1 cm-thick coronal slices. The postmortem MPRAGE image was registered to the MPRAGE image of the fixed hemisphere using nonlinear registration tools. The postmortem MPRAGE and FLAIR image was reoriented to the location of MRI-sensitive markers. The registration between postmortem MRIs and each brain slice was visually inspected and manually corrected [16].

MRI-pathology correlations

Postmortem in situ MRIs were co-registered with cm-thick coronal brain slices of 10 previously characterized MCMS cases [10]. Cm-thick brain slices containing T2 hyperintensities at the occipital horn of the lateral ventricle were cut into two 0.5 cm-thick slices. One slice was embedded in paraffin, sectioned at thickness of 10 µm, stained with PLP antibodies (clone AA3, 1:100; gift from Wendy Macklin, University of Colorado, Aurora, CO) using the avidin-biotin complex and diaminobenzidine procedure [2], and examined for demyelinated lesions in cerebral WM and cerebral cortex. Additional 10 µm-thick paraffin hemispheric sections were stained with Hematoxylin and Eosin (H&E) and analyzed for periventricular small vessel disease (SVD) using standard protocols for perivascular space area and vessel sclerotic index [30, 47]. The other 0.5 cm-thick slice was used for immunocytochemical studies comparing periventricular myelinated axonal pathology in MCMS and age-matched control brains. T2-hyperintensity-positive periventricular myelinated WM in the other 0.5 cm-thick posterior hemispheric slice was removed, sectioned at a thickness of 30 µm, double-labelled for myelin (PLP antibody, 1:100) and axons (mouse anti-phosphorylated and non-phosphorylated neurofilament antibodies, SMI31 and SMI32: 1:1000 dilutions; Bio Legend), and Alexa flour 488 anti-mouse and Alexa flour 594 anti-rat secondary antibodies (diluted 1:1000; Thermofisher Scientific), and then examined by confocal microscopy. Axon densities and axon diameters were calculated as described previously using the tile scanning feature of the Leica SP8 confocal microscope [16, 43] and measured separately at 0.75 mm intervals from the ventricular surface. Multiple nonoverlapping images at 63x magnification were stitched together to create an 27×104 µm2 image for quantification of axonal density and axonal diameter using Image J [43]. All quantifications were performed in a blinded fashion.

Calibration of T1 hypointensity measurements

We investigated the impact of two different 3D T1-weighted sequences on T1 hypointensity volume measurement: MPRAGE and FLASH. Thirty-five brains were scanned in situ with both protocols at 1mm isotropic resolution. Both images were processed independently and T1 hypointensities were segmented automatically (Fig. S2).

The T1 hypointensity volume measurements from MPRAGE and FLASH were highly correlated, and the measures were linearly calibrated using the following equation:T1 hypointensity volume ConvertedMPRAGE=1.5327×T1 hypointensity volumeFLASH

Application of the MRI classifier to PwMS

We applied the postmortem image classifier to the baseline MRIs collected in the Phase II, placebo-controlled, randomized, double-blind, multi-center clinical trial of ibudilast in progressive MS (SPRINT-MS, NCT01982942) [17]. The SPRINT-MS trial enrolled 255 people from 28 United States sites with either Primary Progressive MS or Secondary Progressive MS, age ≤65 years. Patient characteristics were mean age 58 yrs, 47% female, median disease duration 10 years, 53% with Primary Progressive MS and Expanded Disability Status Scale (EDSS) range 3.0–6.5. MRIs were obtained using either GE or Siemens 3T systems. T2 lesion volumes, T1 lesion volumes, and T1/T2% were determined according to the MRI classifier. MRI volumes of whole brain, cerebral WM, cerebral gray matter, and cortical thickness were described previously [14, 31]. MRI characteristics were correlated with clinical data obtained at study baseline [17].

Statistical analyses

Investigators were blinded to MS classification for quantitative analyses of all datasets. Statistical analyses included unpaired t-tests (to compare normally distributed continuous histopathological measurements and MRI measurements between the MCMS group and the TMS or non-neurological control group), and Mann-Whitney U tests (to compare non-normally distributed histopathological measurements and MRI measurements between the MCMS group and the TMS or non-neurological control group). For in vivo MRI analyses, t-tests on baseline variables and calculations of linear correlation coefficients (to evaluate the associations between T1 lesion volume and EDSS) were performed. Welch corrections were used if a dataset failed to show equal variance in an F-test. A Chi square test was used for categorical datasets. For all statistical analyses, two-sided P values of 0.05 or less were considered significant.

Results

MRI classifier

Using MRI sequences and brain slices obtained from previously characterized postmortem MCMS (10 cases) and TMS (12 cases) brains, a classifier that uses T1 hypointensity volume and the percentage of T2 hyperintensity volume occupied by T1 hypointensity volume (T1/T2% ratio) was developed. Since T1 hypointensities vary within and between brains, we systematically obtained T1 thresholds that differentiated MCMS from TMS brains (Fig. 1). The ROC curves were obtained from different T1 hypointensity thresholds and T1/T2% ratios. The optimal (Youden’s) cut point with the greatest sensitivity and specificity to discriminate MCMS from TMS cases was a threshold T1 lesion volume < 0.75 ml (specificity 75%, sensitivity 90%, and accuracy 82%) and T1/T2 % ratio < 1.9% (specificity 92%, sensitivity 70%, and accuracy 82%) (Fig. 1a and b, Table 2). The area under the curve (AUC) that discriminated MCMS from TMS was 0.87, (95% CI 0.64–0.96) for T1 hypointensity volume and 0.89 (95% CI 0.58–0.94) for T1/T2% ratio (Fig. 1a and b). All 22 brains (10 MCMS and 12 TMS) had T2 volumes > 2.0 ml. The spatial distributions of T1-weighted lesions were different in probability maps of TMS and MCMS brains (Fig. 1c and d). The T1 lesion probability in lesion voxels was higher in TMS (0-46%) compared to MCMS (0-16%) (Fig. 1c and d). The MRI classifier thus reliably distinguished previously-characterized MCMS and TMS cases.

Three-dimensional renderings of T2 and T1 lesions in TMS and MCMS

Using the classifier described above, three-dimensional renderings of T2 and T1 lesions were visualized in previously characterized postmortem brains from the 10 MCMS and 12 TMS cases [43]. The majority of T2 hyperintensities in both MCMS and TMS cases had a contiguous periventricular distribution that expanded at the occipital horn of the lateral ventricles (Fig. 2a and b). TMS brains also had focal WM T2 hyperintensities not contiguous with periventricular T2 hyperintensities (Fig. 2a). Total T2-hyperintensity volume was significantly greater in TMS (43.81 ml [SD 27.06]) compared to MCMS (23.08 ml [SD 12.98]; P = 0.032; Welch corrected unpaired t-tests; Fig. 2c). In MCMS, T1 hypointensities were rare, relatively small, and located near the surface of the lateral ventricles (Fig. 2b). Mean total T1 hypointensity volumes were significantly lower in MCMS (0.265 ml [IQR 0.067–0.722]) compared to TMS (1.95 ml [IQR 0.63–10.52]; P = 0.0026; Mann-Whitney U test; Fig. 2d). Similarly, the percentages of T1 hypointensity volume within T2 lesions were significantly lower in MCMS (1.736% [SD 1.462]) compared to TMS (10.92% [SD 8.945]; P = 0.0045; Welch corrected unpaired t-tests; Fig. 2e). Myelinated T2 hyperintensities in postmortem MCMS brains have a contiguous periventricular distribution that expands at the occipital horn of the lateral ventricle.Fig. 2 Three-dimensional distribution of T2 hyperintensities and T1 hypointensities in typical and myelocortical postmortem MS brains. a-b Three-dimensional maps of T2 hyperintensities (yellow) and T1 hypointensities (green) in postmortem TMS (a) and MCMS brains (b). T2 hyperintensities in both TMS and MCMS brains had a contiguous periventricular distribution that expanded at the occipital horn. T1 hypointensities were abundant in TMS (a, green) and were rare in MCMS (b, green). c-e Quantification of T2 volume (c), T1 volume (d), and T1/T2% ratio (e) in TMS and MCMS brains. f-g Postmortem T2-weighted and T1-weighted images co-registered with PLP-stained hemispheric brain sections from TMS (f) and MCMS (g) confirmed demyelination of T1 hypointensities in TMS (white arrows) and the paucity of WM demyelination in MCMS. Cortical demyelination (red) was present in PLP-stained sections from TMS and MCMS brains (scale bar = 2 mm). h-i Quantification of the percentages of cerebral WM demyelinated area (h) and cortical demyelinated area (i) in PLP-stained sections. N = 12 TMS and 12 MCMS postmortem brains

Since 3D rendering consistently show expansion of T2 hyperintensities at the occipital horns of the lateral ventricles (Fig. 2a and b), we co-registered posterior cm-thick hemispheric brain slices (from the 12 TMS cases and 10 MCMS cases) with T2 hyperintensities and T1 hypointensities (Fig. 2f and g). The hemispheric slices were processed for immunocytochemical detection of myelin (Fig. 2f and g). In TMS cases, T1 hypointensities co-localized within T2 hyperintensities that were demyelinated in the stained hemispheric section (Fig. 2f). In contrast, T1 hypointensities and demyelination were not prominent features of periventricular T2 lesions in MCMS cases (Fig. 2g). The percent area of cerebral WM demyelination was significantly lower in MCMS (0.076% [IQR 0.001–0.710]) than in TMS cases (4.906% [IQR 0.351–15.73]; P = 0.002; Mann-Whitney U test; Fig. 2h), while the percent areas of subpial cortical demyelination were similar (Fig. 2i). These data establish a paucity of cerebral WM demyelination associated with the occipital horn of the lateral ventricle in MCMS cases.

Neuropathological changes in the periventricular region

While periventricular demyelination was not a prominent feature in 10 µm-thick hemispheric sections from MCMS cases (Fig. 2b), reduced myelin density was apparent in periventricular regions of the occipital horn (Fig. 3a-c). Therefore, we compared myelinated axon densities and myelinated axon diameters in periventricular regions of MCMS and aged-matched control brains double-labelled for myelin and axons. All axons in control and myelocortical periventricular WM were surrounded by PLP-positive myelin (Fig. 3d). Compared to age-matched control sections, MCMS sections contained a surface-in gradient of reduced myelinated axon densities (Fig. 3e-g) and increased myelinated axonal diameters (Fig. 3h). When examined at higher magnification (Fig. 3i-l), several patterns of myelinated axonal pathology were detected in periventricular regions of MCMS cases. Compared to control cases where periventricular myelinated axons had small diameters (Fig. 3i), myelocortical myelinated fibers had increased axonal diameters (Fig. 3j), focal axonal swellings (Fig. 3k), and discontinuous myelin ovoids without axons (Fig. 3l). Ongoing myelinated axonal degeneration was associated with decreased myelinated fiber density in periventricular WM in MCMS. These data establish a surface-in gradient of myelinated axon degeneration in the occipital horn from MCMS cases.Fig. 3 Degeneration of myelinated axons in MCMS periventricular WM. a-c Comparison of myelin staining (PLP antibody) in periventricular regions of control (a) and MCMS (b) brain sections (scale bar = 2 mm) obtained from the occipital horn of the lateral ventricle identified reduced myelin fiber density in MCMS sections (b, c) (c, scale bar = 1 mm). d Confocal analyses of PLP (red) and neurofilament (green) staining indicated that axons were surrounded by PLP-positive myelin in both control and MCMS sections (scale bar = 20 µm). e-f Axons in cerebral WM of non-neurological control (e) and MCMS (f) sections at 0.75 mm intervals from the ventricular surface (scale bar = 100 µm). g-h Axonal densities were decreased (g) and axonal diameters were increased (h) in MCMS segments compared to control segments. i-l Upper panels compare neurofilament-stained axons in control (i) and MCMS (j-l) periventricular WM. Lower panels indicate that all neurofilament-positive axons (green) are surrounded by PLP-positive myelin (red). Myelinated fibers in control sections have small diameters (i). MCMS sections contained axonal swellings (j), axonal ovoids (k), and myelinated axon degeneration (l, myelin debris without axons, arrows) (i-l, scale bar = 30  µm). Lower panels are double-labelled with PLP and neurofilament. g-h N = 8 control cases and 10 MCMS cases

Validation of the MRI classifier in postmortem cases

We then applied the classifier to 36 uncharacterized postmortem brains (Fig. 4). Seven cases with T1 lesion volume < 0.75 ml and T1/T2% ratio < 1.9% were identified as possible MCMS cases compared to twenty-nine as possible TMS (Table 3 and Table S1). Total T2 lesion volume was similar between TMS and MCMS (Fig. 4a), whereas T1 lesion volume (Fig. 4b: TMS 2.49 ml [IQR 0.80–5.45] vs MCMS 0.12 ml [0.07–0.32]; P < 0.0001; Mann-Whitney U test) and T1/T2% ratio (Fig. 4c: TMS 5.57 ml [IQR 3.32–10.22] vs MCMS 0.42 ml [0.26–0.83]; P < 0.0001; Mann-Whitney U test) was significantly greater in TMS postmortem brains. Brain atrophy measures were similar across TMS and MCMS (Table 3). The paucity of cerebral WM hyperpigmentation (< 0.4 cm2) [43] in cm-thick hemispheric brain slices and the lack of cerebral WM lesions in PLP-stained paraffin sections from hemispheric brain slices (containing the occipital horn of the lateral ventricle) indicated that six of these seven cases were MCMS (Fig. 4d and e). Pathological examination identified one MCMS as TMS (Fig. S3). The classifier differentiated between MCMS and TMS with a sensitivity of 85.7%, specificity of 96.5%, and accuracy of 94.4%. The area of cerebral WM hyperpigmentation in cm-thick brain slices (28-32 per brain) was significantly lower in MCMS (0.15 cm2 [IQR 0.00–0.30]) compared to TMS cases (1.67 cm2 [IQR 0.74–4.49]; P < 0.0001; Mann-Whitney U test; Fig. 4f). To meet the pathological criteria for MCMS requires spinal cord demyelination. Therefore, we stained MCMS spinal cord segments for myelin with PLP antibodies. Spinal cords from 5 of the MCMS cases contained WM demyelinated lesions (Fig. 4g; spinal cord from one MCMS was not available). When applied to 36 uncharacterized postmortem brains, the classifier identified 6 MCMS cases.Fig. 4 Validation of the classifier in 36 uncharacterized postmortem MS brains. a-c The classifier identified 29 TMS and 7 MCMS cases. MCMS brains had T2LV > 2 ml (a), T1 lesion volume < 0.75 ml (b) and T1/T2% ratio < 1.9 (c). d Representative images of cm-thick brain slices from 4 TMS brains. Macroscopic WM discolorations (arrows) indicate demyelination. e Co-registration of cm-thick hemispheric brain slices and myelin-stained sections from 7 MCMS cases identified by the classifier failed to detect WM hyperpigmentation in cm-thick slices nor demyelination in PLP-stained sections in 6 cases (scale bar = 10 mm). One MCMS case had WM hyperpigmentation volume > 0.04 cm2 and was identified as an MCMS false-positive. f Comparison of cerebral WM hyperpigmentation between TMS and MCMS brains. g Spinal cord demyelination was present in 5 MCMS cases (spinal cord was not available from one case; scale bar = 200 µm)

Table 3 The clinical, imaging, and pathological characteristics of the postmortem validation cohort after stratification

	TMS	MCMS	P value	
Count	29	7	NA	
Age (years), median (IQR)	55 (50-60)	56 (52-61)	0.52	
Female %	62%	85.7%	0.23	
Primary progressive/secondary progressive/relapsing remitting	8/17/4	2/5/0	NA	
T2 lesion volume (ml), median (IQR)	47.40 (27.45)	35.24 (15.51)	0.27	
T1 lesion volume (ml), median (IQR)	2.49 (0.80-5.45)	0.12 (0.07-0.32)	< 0.0001	
T1/T2 %, median (IQR)	5.57 (3.32-10.22)	0.42 (0.26-0.83)	< 0.0001	
Brain parenchymal fraction, mean (SD)a	0.72 (0.08)	0.72 (0.08)	0.96	
White matter fraction, median, (IQR)b	0.44 (0.41-0.47)	0.42 (0.3-0.48)	0.49	
Grey matter fraction, mean (SD)c	0.28 (0.05)	0.31 (0.04)	0.21	
Expanded disability status scale, median (IQR)	8 (7.2-9.0)	7.5 (7-8)	0.19	
Disease Duration (years), mean (SD)	22 (9)	24 (5)	0.77	
Cerebral white matter macroscopic lesion area per hemisphere (cm2), median (IQR)	1.67 (0.74–4.49)	0.15 (0.00-0.3)	< 0.0001	
Data missing for aBPF (TMS n = 1)

bWMF (TMS n = 1 and MCMS n = 1)

cGMF (TMS n = 1 and MCMS n = 1)

MRI classifier applied to PwMS

The imaging classifier was then applied to the baseline MRIs of 255 progressive MS patients enrolled in the SPRINT-MS trial. Patient characteristics include mean age 58 yrs, 47% female, median EDSS 6.0, median disease duration 10 years, and 53% with Primary Progressive MS. Based upon quantitative measures of T2 hyperintensities and T1 hypointensities, the classifier identified 199 TMS patients (Fig. 5a) and 25 MCMS patients (Fig. 5b). Thirty-one SPRINT-MS patients did not meet inclusion criteria for distinguishing MCMS and TMS because they had < 2 ml of total T2 lesion volume (Low T2 MS group; Fig. 5c). Total T2-hyperintensity volumes were similar between TMS and MCMS (Table 4 and Fig. 5d) whereas T1 hypointensity volumes were significantly greater in TMS patients (TMS 0.86 ml [IQR 0.28–1.97] vs. MCMS 0.066 ml [0.027–0.23]; P < 0.0001; Mann-Whitney U test) (Table 4 and Fig. 5e). Compared to TMS, the low T2 MS group had significantly lower T1 hypointensity volumes (Table 4 and Fig. 5e, TMS 0.86 ml [IQR 0.28–1.97] vs. low T2 0.061 ml [0.025–0.086]; P < 0.0001; Mann-Whitney U test). In summary, 78% of SPRINT-MS patients were classified as TMS (T2 hyperintensity volume > 2 ml, T1 hypointensity volume > 0.75 ml and T1/T2% > 1.9% or T1 hypointensity volume > 0.75 ml and T1/T2% < 1.9% or T1 hypointensity volume < 0.75 ml and T1/T2% > 1.9%), 10% were classified as MCMS (T2 hyperintensity volume > 2 ml, T1 hypointensity volume < 0.75 ml; T1/T2% < 1.9%) and 12% were classified as Low T2 (T2 hyperintensity volume < 2 ml and a paucity of T1 hypointensities averaging 0.061 ml).Fig. 5 MRI classifier applied to 255 MS participants enrolled in the SPRINT-MS trial. a-c The MRI classifier identified 199 TMS cases (a), 25 MCMS cases (b), and 31 cases with T2 volume < 2 ml and a paucity of T1 hypointensities (c, Low T2). d-e Comparison of T2-hyperintensity volume (d) and T1-hypointensity volume (e) in TMS, MCMS, and Low T2 brains. f Spearman’s correlation between T1-hypointensity volume and EDSS across 199 TMS, 25 MCMS, and 31 Low T2 MS

Table 4 The baseline clinical and imaging characteristics of SPRINT-MS trial participants after stratification

	TMS	MCMS	Low T2 MS	TMS vs MCMS,
P value	TMS vs
low T2 MS,
P value	MCMS vs low T2 MS, P value	
Count	199	25	31	NA	NA	NA	
Age (years), mean (SD)	55.7(7.3)	56.7(6.5)	53.8(7.7)	0.63	0.19	0.2	
Female %	54.3%	44.0%	54.8%	0.49	1.0	0.59	
Primary progressive/secondary progressive	98/101	14/11	22/9	0.67	0.04	0.38	
Brain parenchymal fraction, Median (IQR)	0.805

(0.788–0.821)

	0.804

(0.783–0.819)

	0.829

(0.811–0.845)

	0.96	< 0.0001	0.001	
T2 lesion volume (ml), median

(IQR)

	11.95

(5.32–22.71)

	8.70

(3.82–17.13)

	1.55

(1.17–1.78)

	0.26	< 0.0001	< 0.0001	
T1 lesion volume (ml) median

(IQR)

	0.86

(0.28–1.97)

	0.066

(0.027–0.23)

	0.061

(0.025–0.086)

	< 0.0001	< 0.0001	0.18	
T1/T2 % median

(IQR)

	6.15

(3.94–11.31)

	1.00

(0.54–1.69)

	3.87

(1.75–7.01)

	< 0.0001	0.0006	< 0.0001	
White matter fraction, median

(IQR)

	0.345

(0.331–0.357)

	0.351

(0.334–0.367)

	0.356

(0.347–0.364)

	0.26	0.0024	0.24	
Grey matter fraction, mean (SD)	0.458(0.020)	0.453(0.022)	0.472(0.016)	0.25	0.0004	0.0006	
Cortical thickness (mm), median

(IQR)

	3.402

(3.250–3.539)

	3.395

(3.264–3.559)

	3.569

(3.470–3.701)

	0.91	< 0.0001	< 0.0001	
Lesional MTR, median

(IQR)a

	38.89

(36.94–41.20)

	42.65

(39.81–44.55)

	41.35

(39.13–42.88)

	< 0.0001	0.0003	0.21	
EDSS, median (IQR)	6(3~7)	6(4~6.5)	6(2.5~6.5)	0.08	0.359	0.04	
Disease duration (Years), median (IQR)	11

(0~41)

	9

(0~34)

	7

(0~29)

	0.66	0.059	0.34	
Timed 25-ft walk (Sec), median (IQR)	9.55 (6.85–16.63)	11.85 (7.65–28.45)	8.5 (6.13–11.7)	0.59	0.60	0.16	
9-hole peg test (Sec), median (IQR)	29.83 (25.09–40.27)	35.43 (29.9–45.33)	24.53 (21.03–27.18)	0.12	0.0008	< 0.0001	
Symbol digit modalities test- no of correct answers, Mean (SD)	42.08 (14.61)	39.64 (14.23)	48.5 (11.25)	0.69	0.057	0.057	
aMTR magnetization transfer ratio

bEDSS expanded disability status scale

TMS and MCMS participants had similar disability scores (EDSS), disease duration, reduced whole-brain, WM, and GM volumes, and similar degrees of cortical thinning (Table 4). The low T2 group had lower disability scores and less brain atrophy compared to TMS and MCMS (Table 4). There was no correlation between EDSS and T1 hypointensity volume (Fig. 4f) in TMS (r = 0.03), MCMS (r = 0.16), or low T2 (r = 0.20) patients (Table 4 and Fig. 5f). The SPRINT-MS trial enrolled 134 PPMS and 121 SPMS participants: 50% percent of TMS, 56% of MCMS, and 71% of low T2 participants were identified as PPMS (Table 4).

Discussion

We developed an MRI classifier that reliably identified previously-characterized postmortem MCMS brains with a paucity of cerebral WM demyelination by co-registrations of the MRIs and myelin pathology in tissue sections. The classifier was validated in 36 uncharacterized postmortem MS brains and identified 6 MCMS cases with 94% accuracy by macroscopic assessment of brain slices and myelin staining of tissue sections. An advantage of the classifier described here is that it utilizes imaging sequences that are routinely performed in the clinic and in MS clinical trials. The imaging classifier identified a contiguous periventricular distribution of myelinated T2 hyperintensities in postmortem MCMS brains that expanded at the occipital horn of the lateral ventricles where a surface-in gradient of myelinated fiber degeneration was detected. This adds to the growing evidence that a surface-in mechanism of neurodegeneration is operating in MS [27, 28]. When applied to 255 PMS participants enrolled in SPRINT-MS, the classifier identified 25 MCMS cases. These MCMS patients had similar disability scores (EDSS) and cortical thinning as TMS patients, supporting the concept that neurological disability and cortical atrophy can occur independent of cerebral WM demyelination. By leveraging postmortem and clinical MRI signatures, our studies support the utilization of an MRI classifier for establishing inclusion criteria and outcome measures for future PMS clinical trials. The clinical implications of this work are important, as the absence of cerebral WM demyelination was a relatively common finding, and inclusion of these patients in potential remyelination trials may dilute power. The use of the classifier to enrich study populations with demyelination would be a major added value for recruitment in remyelination trials or in post hoc analysis of already-completed trials.

This study supports the concept that MS is characterized by an insidious neurodegenerative process evident by widespread cortical atrophy, which can occur independent of superimposed and variable cerebral WM demyelination [4, 24]. Longitudinal studies of two RRMS populations concluded that 80-90% of overall disability progression occurred independently of relapse activity (PIRA) [3, 22, 34, 44, 45]. New focal T2 or Gadolinium-enhancing lesions need not accompany all clinical relapses (ACES) [18]. Our identification of postmortem brains from severely disabled MS cases with a paucity of cerebral WM demyelination provides pathological support of disability independent of significant cerebral WM demyelination. Demyelination of spinal cord white matter, however, is likely to contribute to disability progression in MCMS.

Myelinated T2 hyperintensities have contiguous periventricular distribution in MCMS brains that expands at the occipital pole of the lateral ventricle where a gradient of myelinated axonal loss and degenerating myelinated internodes peaks at the ventricular surface and decreases with distance from this surface. Such a surface-in mechanism of MS pathogenesis is not novel and has been described for the pial surface of the cerebral cortex [27] and third ventricle of the thalamus [28]. Meningeal inflammation in cortical sulci has been proposed as a source of CSF immune-related soluble factors that diffuse into the cortex and cause subpial demyelination of cortical layers I–III [1, 21, 27]. The surface-in gradient at the occipital horn of the lateral ventricle described here, however, differs from that in the cortex in that it does not induce periventricular WM demyelination, targets the integrity of the myelin-axon unit, and its surface is comprised of ependymal cells. Pathological and molecular characterization of ependymal cells in postmortem MCMS brains may help to identify mechanisms of periventricular myelinated axon loss.

Periventricular myelinated T2 hyperintensities are also present in TMS brains. It remains to be determined whether a surface-in mechanism of myelinated axonal degeneration could be segregated from periventricular myelinated axon loss caused by periventricular or cerebral WM demyelination. In either event, the characterization of periventricular axonal degeneration in MCMS identifies a novel disease mechanism that has the potential to contribute to neurological decline in MS and possibly provide a therapeutic target for mitigating neurodegeneration.

Cerebral WM T2 hyperintensities have been associated with SVD. The pathological hallmarks of SVD, lacunar infarcts and microbleeds [43], and small vessel pathology (Fig. S4) are not features of MCMS cerebral WM. However, the possibility that age-related changes other than SVD contribute to periventricular WM changes cannot be excluded. While WM demyelination and SVD are not responsible for periventricular myelinated axonal degeneration in MCMS, subpial cortical and spinal cord demyelination could play a role. Spinal cord pathology is an unlikely source of periventricular myelinated axon pathology as neither motor nor sensory spinal cord axons transverse periventricular WM. The extent of cortical demyelination was similar in posterior regions of MCMS and TMS (Fig. 2i), while a previous study of parietal sections reported greater cortical demyelination in TMS [43]. In addition to a surface-in gradient, Wallerian degeneration due to cortical neuronal loss could contribute to periventricular myelinated fiber loss.

Our data supports disability with minimal cerebral WM demyelination in 22% of progressive MS patients enrolled in SPRINT–MS. The best correlates of disability at all stages of MS (clinically isolated syndrome through SPMS) are GM atrophy and cortical thinning [11, 12, 19]. Neurological disability (Table 3) and cortical neuronal loss were similar in postmortem MCMS and TMS brains [43] and neurological disability and cortical thinning were similar in TMS and MCMS participants enrolled in SPRINT-MS (Table 4). These data support the concept that cortical neuronal loss and cortical thinning can occur independent of cerebral WM demyelination.

The MS classifier distinguished pathologically confirmed postmortem MCMS and TMS cases with an accuracy of ~94%. The percentage of MCMS cases identified by the MRI classifier was similar in postmortem and SPRINT-MS cohorts. SPRINT-MS trial participants, however, had less T1 and T2 lesion volumes, reflecting their lower age, shorter disease duration, and perhaps greater access to disease-modifying therapies. Twelve percent of SPRINT-MS patients had a paucity of T2 and T1 abnormalities. The finding of a group of patients with low T2 and T1 abnormalities is not surprising, as there have long been descriptions of patients with lower brain lesion loads, particularly in those with PP forms of MS [8] or spinal cord-predominant forms of the disease [32]. SPRINT-MS patients with low T2 lesions were predominantly PPMS (22/31) and compared to TMS had significantly less MRI measures of atrophy and performed better on neural performance testing (Table 4). In summary, patients with low T2 lesion volumes appeared to have a milder form of MS. It remains to be determined if they form a distinct entity or simply reflect the lower end of the biological, clinical, and/or radiological variability that occurs in MS.

There are limitations to this study. First, it is a cross-sectional study of postmortem brains from the Cleveland Clinic and living progressive MS patients enrolled in the SPRINT-MS clinical trial. Pathological findings need to be confirmed in other autopsy cohorts and future longitudinal studies of PwMS are needed to verify MRI-based subclasses at earlier stages of MS and investigate how MRI subclasses respond to different therapeutics in clinical trials. T1 hypointensities are less specific to myelin than advanced MRI sequences such as myelin water imaging [25], magnetization transfer imaging [39], and ultrashort echo imaging [40]. While our inclusion of T1 intensity thresholds identified MCMS and TMS with an accuracy of 94%, application of these advanced MRI sequences may further optimize classifier performance. Features other than demyelination could influence the classifier. In addition to demyelination, acute lesions have increased cellular [35] and water content [13], while chronic lesions have variable degrees of tissue damage [16]. Intracortical and subpial cortical lesions may influence values of cortical T1 hypointensity thresholds, although the effect is likely small. The inclusion of MRI data acquired with different protocols and pulse sequences may influence classifier performance. Spinal cord MRI data was not included in the SPRINT-MS trial. The addition of spinal cord MRIs in future MS clinical trials would help to address the role of spinal cord disease in MS subgroups. Using pathological specimens to inform changes in people living with MS has inherent challenges; we have tried to mitigate these by 1) using MRI performed very close to the time of death, and 2) recapitulating pathology data in a clinical trial dataset. Our findings, however, may not apply uniformly to all stages of MS, particularly at early stages where the factors governing the disease process may differ.

Overall, accumulating evidence raises questions as to cerebral WM demyelination being the major cause of permanent neurological disability in all individuals with MS and supports the concept that global cortical atrophy also drives disability progression in MS. The implications of transforming a fundamental aspect of MS pathogenesis that has dominated MS research for decades are daunting and will require a better understanding of disease mechanisms that drive cortical atrophy. In this regard, pathological studies support a surface-in gradient of neurodegeneration at the pial surface of the cerebral cortex, 3rd ventricle of the thalamus, and the posterior horn of the lateral ventricle, implicating a cerebrospinal fluid (CSF) -associated mechanism of neurodegeneration. Implications of the SPRINT-MS data raise the possibility that an imaging classifier can be used to stratify MS patients in clinical trials and eventually to facilitate personalized application of MS therapies.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (PDF 768 KB)

Acknowledgements

This work was supported by grants from US National Institutes of Health (Grant No.: R35NS09730 to BDT) and National Multiple Sclerosis Society (RFA-2203-39319 to BDT). KN was funded by the US Department of Defense (W81XWH2110787). We thank Cleveland Clinic Mellen Center Neurologists and LifeBanc, Cleveland, OH, for assistance in identifying tissue donors and Dr. Christopher Nelson for editorial assistance.

Author contributions

VS, YZ, KN and BDT designed the study. VS and YZ generated data. VS, YZ, KRM, JH, DO, RJF, KN and BDT participated in data analyses. VS, YZ, KN and BDT generated the first draft of the report. VS, YZ, DO, KRM, JH, RJF, KN and BDT produced the submitted report. VS and YZ are co-first authors.

Data availability

The data that support the findings described in this study are available from the corresponding author, BDT, upon reasonable request and execution of an institutional data transfer agreement.

Declarations

Conflict of interest

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Vikas Singh and Yufan Zheng these authors equally contributed to this work.
==== Refs
References

1. Bevan RJ Evans R Griffiths L Watkins LM Rees MI Magliozzi R Meningeal inflammation and cortical demyelination in acute multiple sclerosis Ann Neurol 2018 84 6 829 842 10.1002/ana.25365 30362156
Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, Magliozzi R et al (2018) Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol 84(6):829–842. 10.1002/ana.2536530362156 10.1002/ana.25365
2. Bö L Mörk S Kong PA Nyland H Pardo CA Trapp BD Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions J Neuroimmunol 1994 51 2 135 146 10.1016/0165-5728(94)90075-2 8182113
Bö L, Mörk S, Kong PA, Nyland H, Pardo CA, Trapp BD (1994) Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 51(2):135–146. 10.1016/0165-5728(94)90075-28182113 10.1016/0165-5728(94)90075-2
3. Cagol A Schaedelin S Barakovic M Benkert P Todea R-A Rahmanzadeh R Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis JAMA Neurol 2022 79 7 682 692 10.1001/jamaneurol.2022.1025 35575778
Cagol A, Schaedelin S, Barakovic M, Benkert P, Todea R-A, Rahmanzadeh R et al (2022) Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 79(7):682–692. 10.1001/jamaneurol.2022.102535575778 10.1001/jamaneurol.2022.1025
4. Calabrese M Preziosa P Scalfari A Colato E Marastoni D Absinta M Determinants and biomarkers of progression independent of relapses in multiple sclerosis Ann Neurol 2024 96 1 20 10.1002/ana.26913 38568026
Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M et al (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 96:1–20. 10.1002/ana.2691338568026 10.1002/ana.26913
5. Chan D Binks S Nicholas JM Frost C Cardoso MJ Ourselin S Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial Lancet Neurol 2017 16 8 591 600 10.1016/S1474-4422(17)30113-8 28600189
Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S et al (2017) Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol 16(8):591–600. 10.1016/S1474-4422(17)30113-828600189 10.1016/S1474-4422(17)30113-8
6. Chataway J De Angelis F Connick P Parker RA Plantone D Doshi A Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial Lancet Neurol 2020 19 3 214 225 10.1016/S1474-4422(19)30485-5 31981516
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A et al (2020) Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol 19(3):214–225. 10.1016/S1474-4422(19)30485-531981516 10.1016/S1474-4422(19)30485-5
7. Cree BA Cutter G Wolinsky JS Freedman MS Comi G Giovannoni G Safety and efficacy of md1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 2020 19 12 988 997 10.1016/S1474-4422(20)30347-1 33222767
Cree BA, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G et al (2020) Safety and efficacy of md1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 19(12):988–997. 10.1016/S1474-4422(20)30347-133222767 10.1016/S1474-4422(20)30347-1
8. Dastagir A Healy BC Chua AS Chitnis T Weiner HL Bakshi R Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis eNeurologicalSci 2018 12 42 46 10.1016/j.ensci.2018.07.002 30229136
Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R et al (2018) Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci 12:42–46. 10.1016/j.ensci.2018.07.00230229136 10.1016/j.ensci.2018.07.002
9. De Groot C Bergers E Kamphorst W Ravid R Polman C Barkhof F Postmortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p) reactive lesions Brain 2001 124 8 1635 1645 10.1093/brain/124.8.1635 11459754
De Groot C, Bergers E, Kamphorst W, Ravid R, Polman C, Barkhof F et al (2001) Postmortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p) reactive lesions. Brain 124(8):1635–1645. 10.1093/brain/124.8.163511459754 10.1093/brain/124.8.1635
10. Dutta R Mahajan KR Nakamura K Ontaneda D Chen J Volsko C Comprehensive autopsy program for individuals with multiple sclerosis J Vis Exp 2019 149 e59511 10.3791/59511
Dutta R, Mahajan KR, Nakamura K, Ontaneda D, Chen J, Volsko C et al (2019) Comprehensive autopsy program for individuals with multiple sclerosis. J Vis Exp 149:e59511. 10.3791/5951110.3791/59511
11. Eshaghi A Marinescu RV Young AL Firth NC Prados F Jorge Cardoso M Progression of regional grey matter atrophy in multiple sclerosis Brain 2018 141 6 1665 1677 10.1093/brain/awy088 29741648
Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M et al (2018) Progression of regional grey matter atrophy in multiple sclerosis. Brain 141(6):1665–1677. 10.1093/brain/awy08829741648 10.1093/brain/awy088
12. Eshaghi A Prados F Brownlee WJ Altmann DR Tur C Cardoso MJ Deep gray matter volume loss drives disability worsening in multiple sclerosis Ann Neurol 2018 83 2 210 222 10.1002/ana.25145 29331092
Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ et al (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83(2):210–222. 10.1002/ana.2514529331092 10.1002/ana.25145
13. Faizy TD Thaler C Kumar D Sedlacik J Broocks G Grosser M Heterogeneity of multiple sclerosis lesions in multislice myelin water imaging PLoS One 2016 11 3 e0151496 10.1371/journal.pone.0151496 26990645
Faizy TD, Thaler C, Kumar D, Sedlacik J, Broocks G, Grosser M et al (2016) Heterogeneity of multiple sclerosis lesions in multislice myelin water imaging. PLoS One 11(3):e0151496. 10.1371/journal.pone.015149626990645 10.1371/journal.pone.0151496
14. Fisher E, Cothren Jr RM, Tkach JA, Masaryk TJ, Cornhill JF (1997) Knowledge-based 3D segmentation of the brain in MR images for quantitative multiple sclerosis lesion tracking In: SPIE Medical Imaging 1997. SPIE, pp 599-610.
15. Fisher E Rudick R Simon J Cutter G Baier M Lee J-C Eight-year follow-up study of brain atrophy in patients with MS Neurology 2002 59 9 1412 1420 10.1212/01.wnl.0000036271.49066.06 12427893
Fisher E, Rudick R, Simon J, Cutter G, Baier M, Lee J-C et al (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59(9):1412–1420. 10.1212/01.wnl.0000036271.49066.0612427893 10.1212/01.wnl.0000036271.49066.06
16. Fisher E Chang A Fox RJ Tkach JA Svarovsky T Nakamura K Imaging correlates of axonal swelling in chronic multiple sclerosis brains Ann Neurol 2007 62 3 219 228 10.1002/ana.21113 17427920
Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K et al (2007) Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 62(3):219–228. 10.1002/ana.2111317427920 10.1002/ana.21113
17. Fox RJ Coffey CS Conwit R Cudkowicz ME Gleason T Goodman A Phase 2 trial of ibudilast in progressive multiple sclerosis N Engl J Med 2018 379 9 846 855 10.1056/NEJMoa1803583 30157388
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A et al (2018) Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med 379(9):846–855. 10.1056/NEJMoa180358330157388 10.1056/NEJMoa1803583
18. Gavoille A Rollot F Casey R Kerbrat A Le Page E Bigaut K Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis JAMA Neurol 2024 10.1001/jamaneurol.2024.1961 38949816
Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K et al (2024) Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis. JAMA Neurol. 10.1001/jamaneurol.2024.196138949816 10.1001/jamaneurol.2024.1961
19. Geurts JJ Calabrese M Fisher E Rudick RA Measurement and clinical effect of grey matter pathology in multiple sclerosis Lancet Neurol 2012 11 12 1082 1092 10.1016/S1474-4422(12)70230-2 23153407
Geurts JJ, Calabrese M, Fisher E, Rudick RA (2012) Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 11(12):1082–1092. 10.1016/S1474-4422(12)70230-223153407 10.1016/S1474-4422(12)70230-2
20. Hauser SL Oksenberg JR The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration Neuron 2006 52 1 61 76 10.1016/j.neuron.2006.09.011 17015227
Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52(1):61–76. 10.1016/j.neuron.2006.09.01117015227 10.1016/j.neuron.2006.09.011
21. Howell OW Reeves CA Nicholas R Carassiti D Radotra B Gentleman SM Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis Brain 2011 134 9 2755 2771 10.1093/brain/awr182 21840891
Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM et al (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134(9):2755–2771. 10.1093/brain/awr18221840891 10.1093/brain/awr182
22. Kappos L Wolinsky JS Giovannoni G Arnold DL Wang Q Bernasconi C Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials JAMA Neurol 2020 77 9 1132 1140 10.1001/jamaneurol.2020.1568 32511687
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132–1140. 10.1001/jamaneurol.2020.156832511687 10.1001/jamaneurol.2020.1568
23. Korteweg T Rovaris M Neacsu V Filippi M Comi G Uitdehaag B Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler J 2009 15 4 465 471 10.1177/1352458508100505
Korteweg T, Rovaris M, Neacsu V, Filippi M, Comi G, Uitdehaag B et al (2009) Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler J 15(4):465–471. 10.1177/135245850810050510.1177/1352458508100505
24. Kuhlmann T Moccia M Coetzee T Cohen JA Correale J Graves J Multiple sclerosis progression: time for a new mechanism-driven framework Lancet Neurol 2023 22 1 78 88 10.1016/S1474-4422(22)00289-7 36410373
Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78–88. 10.1016/S1474-4422(22)00289-736410373 10.1016/S1474-4422(22)00289-7
25. Laule C Moore GW Myelin water imaging to detect demyelination and remyelination and its validation in pathology Brain Pathol 2018 28 5 750 764 10.1111/bpa.12645 30375119
Laule C, Moore GW (2018) Myelin water imaging to detect demyelination and remyelination and its validation in pathology. Brain Pathol 28(5):750–764. 10.1111/bpa.1264530375119 10.1111/bpa.12645
26. Levesque I Sled JG Narayanan S Santos AC Brass SD Francis SJ The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study J Magn Reson Imaging 2005 21 2 103 110 10.1002/jmri.20231 15666408
Levesque I, Sled JG, Narayanan S, Santos AC, Brass SD, Francis SJ et al (2005) The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study. J Magn Reson Imaging 21(2):103–110. 10.1002/jmri.2023115666408 10.1002/jmri.20231
27. Magliozzi R Howell OW Reeves C Roncaroli F Nicholas R Serafini B A gradient of neuronal loss and meningeal inflammation in multiple sclerosis Ann Neurol 2010 68 4 477 493 10.1002/ana.22230 20976767
Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B et al (2010) A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 68(4):477–493. 10.1002/ana.2223020976767 10.1002/ana.22230
28. Magliozzi R Fadda G Brown RA Bar-Or A Howell OW Hametner S “Ependymal-in” gradient of thalamic damage in progressive multiple sclerosis Ann Neurol 2022 92 4 670 685 10.1002/ana.26448 35748636
Magliozzi R, Fadda G, Brown RA, Bar-Or A, Howell OW, Hametner S et al (2022) “Ependymal-in” gradient of thalamic damage in progressive multiple sclerosis. Ann Neurol 92(4):670–685. 10.1002/ana.2644835748636 10.1002/ana.26448
29. Mahad DH Trapp BD Lassmann H Pathological mechanisms in progressive multiple sclerosis Lancet Neurol 2015 14 2 183 193 10.1016/S1474-4422(14)70256-X 25772897
Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 14(2):183–193. 10.1016/S1474-4422(14)70256-X25772897 10.1016/S1474-4422(14)70256-X
30. McAleese KE Walker L Graham S Moya EL Johnson M Erskine D Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease Acta neuropathol 2017 134 459 473 10.1007/s00401-017-1738-2 28638989
McAleese KE, Walker L, Graham S, Moya EL, Johnson M, Erskine D et al (2017) Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta neuropathol 134:459–473. 10.1007/s00401-017-1738-228638989 10.1007/s00401-017-1738-2
31. Nakamura K Fox R Fisher E CLADA: cortical longitudinal atrophy detection algorithm Neuroimage 2011 54 1 278 289 10.1016/j.neuroimage.2010.07.052 20674750
Nakamura K, Fox R, Fisher E (2011) CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 54(1):278–289. 10.1016/j.neuroimage.2010.07.05220674750 10.1016/j.neuroimage.2010.07.052
32. Nociti V Cianfoni A Mirabella M Caggiula M Frisullo G Patanella AK Clinical characteristics, course and prognosis of spinal multiple sclerosis Spinal Cord 2005 43 12 731 734 10.1038/sj.sc.3101798 16010274
Nociti V, Cianfoni A, Mirabella M, Caggiula M, Frisullo G, Patanella AK et al (2005) Clinical characteristics, course and prognosis of spinal multiple sclerosis. Spinal Cord 43(12):731–734. 10.1038/sj.sc.310179816010274 10.1038/sj.sc.3101798
33. Noseworthy JH Progress in determining the causes and treatment of multiple sclerosis Nature 1999 399 6738 A40 A47 10.1038/399a040 10392579
Noseworthy JH (1999) Progress in determining the causes and treatment of multiple sclerosis. Nature 399(6738):A40–A47. 10.1038/399a04010392579 10.1038/399a040
34. Portaccio E Bellinvia A Fonderico M Pastò L Razzolini L Totaro R Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study Brain 2022 145 8 2796 2805 10.1093/brain/awac111 35325059
Portaccio E, Bellinvia A, Fonderico M, Pastò L, Razzolini L, Totaro R et al (2022) Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain 145(8):2796–2805. 10.1093/brain/awac11135325059 10.1093/brain/awac111
35. Prineas JW Lee S Multiple sclerosis: destruction and regeneration of astrocytes in acute lesions J Neuropathol Exp Neurol 2019 78 2 140 156 10.1093/jnen/nly121 30605525
Prineas JW, Lee S (2019) Multiple sclerosis: destruction and regeneration of astrocytes in acute lesions. J Neuropathol Exp Neurol 78(2):140–156. 10.1093/jnen/nly12130605525 10.1093/jnen/nly121
36. Reich DS Lucchinetti CF Calabresi PA Multiple sclerosis New Engl J Med 2018 378 2 169 180 10.1056/NEJMra1401483 29320652
Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. New Engl J Med 378(2):169–180. 10.1056/NEJMra140148329320652 10.1056/NEJMra1401483
37. Rorden C Brett M Stereotaxic display of brain lesions Behav Neurol 2000 12 4 191 200 10.1155/2000/421719 11568431
Rorden C, Brett M (2000) Stereotaxic display of brain lesions. Behav Neurol 12(4):191–200. 10.1155/2000/42171911568431 10.1155/2000/421719
38. Rudick RA Fisher E Lee J-C Duda JT Simon J Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a Mult Scler J 2000 6 6 365 372 10.1177/135245850000600601
Rudick RA, Fisher E, Lee J-C, Duda JT, Simon J (2000) Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a. Mult Scler J 6(6):365–372. 10.1177/13524585000060060110.1177/135245850000600601
39. Schmierer K Scaravilli F Altmann DR Barker GJ Miller DH Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain Ann Neurol 2004 56 3 407 415 10.1002/ana.20202 15349868
Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56(3):407–415. 10.1002/ana.2020215349868 10.1002/ana.20202
40. Sheth V Shao H Chen J Vandenberg S Corey-Bloom J Bydder GM Magnetic resonance imaging of myelin using ultrashort echo time (UTE) pulse sequences: phantom, specimen, volunteer and multiple sclerosis patient studies Neuroimage 2016 136 37 44 10.1016/j.neuroimage.2016.05.012 27155128
Sheth V, Shao H, Chen J, Vandenberg S, Corey-Bloom J, Bydder GM et al (2016) Magnetic resonance imaging of myelin using ultrashort echo time (UTE) pulse sequences: phantom, specimen, volunteer and multiple sclerosis patient studies. Neuroimage 136:37–44. 10.1016/j.neuroimage.2016.05.01227155128 10.1016/j.neuroimage.2016.05.012
41. Sucksdorff M Matilainen M Tuisku J Polvinen E Vuorimaa A Rokka J Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis Brain 2020 143 11 3318 3330 10.1093/brain/awaa275 33006604
Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J et al (2020) Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain 143(11):3318–3330. 10.1093/brain/awaa27533006604 10.1093/brain/awaa275
42. Trapp BD Nave K-A Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008 31 247 269 10.1146/annurev.neuro.30.051606.094313 18558855
Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269. 10.1146/annurev.neuro.30.051606.09431318558855 10.1146/annurev.neuro.30.051606.094313
43. Trapp BD Vignos M Dudman J Chang A Fisher E Staugaitis SM Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study Lancet Neurol 2018 17 10 870 884 10.1016/S1474-4422(18)30245-X 30143361
Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM et al (2018) Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 17(10):870–884. 10.1016/S1474-4422(18)30245-X30143361 10.1016/S1474-4422(18)30245-X
44. Tur C Carbonell-Mirabent P Cobo-Calvo Á Otero-Romero S Arrambide G Midaglia L Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis JAMA Neurol 2023 80 2 151 160 10.1001/jamaneurol.2022.4655 36534392
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L et al (2023) Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 80(2):151–160. 10.1001/jamaneurol.2022.465536534392 10.1001/jamaneurol.2022.4655
45. Cree BA Hollenbach JA Bove R Kirkish G Sacco S Caverzasi E Silent progression in disease activity–free relapsing multiple sclerosis Ann Neurol 2019 85 5 653 666 10.1002/ana.25463 30851128
Cree BA, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E et al (2019) Silent progression in disease activity–free relapsing multiple sclerosis. Ann Neurol 85(5):653–666. 10.1002/ana.2546330851128 10.1002/ana.25463
46. Weinshenker B Bass B Rice G Noseworthy J Carriere W Baskerville J The natural history of multiple sclerosis: a geographically based study: I Clinical course and disability. Brain 1989 112 1 133 146 10.1093/brain/112.1.133 2917275
Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J et al (1989) The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 112(1):133–146. 10.1093/brain/112.1.1332917275 10.1093/brain/112.1.133
47. Yamamoto Y Ihara M Tham C Low RW Slade JY Moss T Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL Stroke 2009 40 6 2004 2011 10.1161/STROKEAHA.108.528299 19359623
Yamamoto Y, Ihara M, Tham C, Low RW, Slade JY, Moss T et al (2009) Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke 40(6):2004–2011. 10.1161/STROKEAHA.108.52829919359623 10.1161/STROKEAHA.108.528299
